Atossa Therapeutics, Inc.
(NASDAQ : ATOS)

( )
ATOS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
ABTAbbott Laboratories 0.89%129.220.8%$691.97m
TMOThermo Fisher Scientific, Inc. 1.49%617.001.0%$687.01m
DHRDanaher Corp. 0.45%308.370.7%$677.93m
MDTMedtronic Plc -0.04%124.050.6%$562.28m
ISRGIntuitive Surgical, Inc. 0.00%348.700.8%$483.87m
ALGNAlign Technology, Inc. -0.05%593.006.3%$373.53m
BDXBecton, Dickinson & Co. -0.05%246.221.0%$294.34m
SYKStryker Corp. -0.15%273.021.3%$269.73m
EWEdwards Lifesciences Corp. -0.12%116.850.4%$269.22m
DXCMDexCom, Inc. 0.00%565.647.8%$268.91m
BSXBoston Scientific Corp. 0.41%44.511.0%$243.69m
AAgilent Technologies, Inc. 0.48%159.001.6%$214.95m
IDXXIDEXX Laboratories, Inc. 0.00%651.963.8%$209.83m
INMDInMode Ltd. 0.45%87.900.0%$193.20m
BAXBaxter International, Inc. 0.01%81.801.8%$184.16m

Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.